• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen is awarded a research grant from “Regione Toscana”

Dec 23, 2015 | 2015, Press Releases, Scientific

Philogen is awarded a research grant from “Regione Toscana” for a project focusing on the development of new strategies of Factor V purification for patients in need thereof. POSTER PROGETTO FV-OD

Dario Neri, the co-founder and Chairman of the Scientific Advisory Board presented at the 11th Annual European Antibody Congress in Basel, Switzerland, 9th-11th November.

Nov 9, 2015 | 2015, Past Events

Dario Neri, the co-founder and Chairman of the Scientific Advisory Board presented at the 11th Annual European Antibody Congress in Basel, Switzerland, 9th-11th November. The title of the talk was “Armed Antibodies for the treatment of Cancer and of Chronic...

Dario Neri, the co-founder and chairman of the scientific advisory board of Philogen will deliver the keynote speech at the First Boston Symposium of Encoded Library Platforms in Boston

Nov 6, 2015 | 2015, Past Events

Dario Neri, the co-founder and chairman of the scientific advisory board of Philogen will deliver the keynote speech at the First Boston Symposium of Encoded Library Platforms in Boston, 6th November. The title of his presentation will be “Single-Pharmacophore and...

Philogen is pleased to announce that it has signed a collaborative agreement with Boehringer Ingelheim

Oct 12, 2015 | 2015, Press Releases, Scientific

Philogen is pleased to announce that it has signed a collaborative agreement with Boehringer Ingelheim to investigate novel treatment approaches for Acute Myeloid Leukemia. Siena (Italy), October 12th. (see full Press Release).

Philogen. Data from Phase Ib clinical trial of Dekavil in rheumatoid arthritis

Sep 27, 2015 | 2015, Past Events

Philogen. Data from Phase Ib clinical trial of Dekavil in rheumatoid arthritis were presented at the 4th Israel-Italy Meeting of Autoimmunity and Autoinflammation: Cutting Edge. Siena (Italy), September 27th-28th.

Philogen attended BIO in Philadelphia, PA (USA), 15th-19th June, 2015.

Jun 12, 2015 | 2015, Past Events

« Older Entries

Recent Posts

  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • La controllata Philochem AG ha concesso in licenza i diritti a livello mondiale su OncoACP3, un nuovo agente terapeutico e diagnostico per il trattamento del cancro alla prostata, a RayzeBio, società del gruppo Bristol-Myers Squibb, per un valore fino a 1,35 miliardi di dollari più royalties.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
  • The MedChem division of the Italian Chemical Society (SCI) awarded two Prizes to Philochem employees: Samuele Cazzamalli (Head of Chemistry) and Sara Puglioli (Research Scientist)
  • Deposito del Verbale dell’Assemblea degli Azionisti

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it